

What is Claimed is:

1. A multispecific antibody specific for human CD3 $\delta\epsilon$, comprising:
 - (i) a first binding moiety that has binding specificity for human CD3 $\delta\epsilon$ and a second binding moiety that has binding specificity for a pathogen antigen, characterized in that, the first binding moiety comprises:
 - a first heavy chain variable domain comprising:
 - (a) a CDR1 sequence of GGSIRSGGHY, a CDR2 sequence of ISYSGST, and a CDR3 sequence of ARWRHDILTAYPYYYYGMDV;
 - and a light chain variable domain comprising a CDR1 sequence comprising QSVSSN, a CDR2 sequence comprising GAS, and a CDR3 sequence comprising QQYNNWPWT in a human VL framework.
2. The multispecific antibody of claim 1, wherein said first heavy chain CDR1, CDR2 and CDR3 sequences are present in a human VH framework.
3. The multispecific antibody of claims 1-2, wherein the first heavy chain variable domain comprises an amino acid sequence set forth in SEQ ID NO: 18.
4. The multispecific antibody of any one of claims 1-3, wherein the light chain variable domain comprises an amino acid sequence of SEQ ID NO: 69.
5. A multispecific antibody of any one of claims 1-4, wherein when contacted with T cells in an activation assay the multispecific antibody induces release of reduced levels of one or both of IL-2 and IL-10 relative to a reference anti-CD3 antibody.
6. The multispecific antibody of any one of claims 1-5, further comprising an Fc region.
7. The multispecific antibody of claim 6, wherein the Fc region has been engineered to reduce effector functions.
8. The multispecific antibody of any one of claims 1-7, wherein the affinity (KD) of the protein for human CD3 delta epsilon is around 10^{-6} M to around 10^{-11} M.

9. The multispecific antibody of any one of claims 1-7, wherein the protein cross-reacts with human and *Cynomolgus* macaque CD3 protein.
10. The multispecific antibody of any one of claims 1-9, wherein the protein comprises a single chain.
11. The multispecific antibody of any one of claims 1-9, wherein the protein comprises two chains, or a multiple thereof.
12. The multispecific antibody of any one of claims 1-9, wherein the protein comprises three chains.
13. The multispecific antibody of any one of claims 1-9, wherein the multispecific antibody comprises three chains and two antigen-binding arms, wherein the first antigen-binding arm comprises an antibody heavy chain and an antibody light chain, and the second antigen-binding arm comprises an antibody heavy chain that does not comprise a CH1 domain.
14. The multispecific antibody of claim 1, wherein the heavy chain variable domain specific for pathogen antigen is a heavy chain only variable domain.
15. The-multispecific antibody of claim 14, wherein the heavy chain variable domain specific for pathogen antigen further comprises a light chain variable domain.
16. The multispecific antibody of claim 14, wherein the light chain variable domain is the same as the light chain variable domain of the CD3 $\delta\epsilon$ -binding region.
17. A pharmaceutical composition comprising multispecific antibody of any of claims 1-16.
18. The pharmaceutical composition of claim 17, in a unit dose formula.
19. A polynucleotide encoding a multispecific antibody of any of claims 1-16.
20. A vector comprising a polynucleotide of claim 19.

21. A cell comprising a vector of claim 20.
22. A method of producing a multispecific antibody of any one of claims 1-16, comprising growing a cell according to claim 21 under conditions permissive for expression of the protein, and isolating the protein from the cells.
23. Use of a multispecific antibody of any one of claims 1-16, in the preparation of a medicament for the treatment of an infection in an individual.
24. The multispecific antibody of any one of claims 1-16, or the pharmaceutical composition of claim 17, for use in therapy in an individual.
25. The multispecific antibody or the pharmaceutical composition according to claim 24 or the use of claim 23, wherein the individual is human.
26. A method of making a multispecific antibody of claim 1, comprising: immunizing OmniFlic or UniRat animals with a pathogen antigen; and identifying antigen-specific heavy chain sequences that can be combined in a molecule containing the multispecific antibody of any one of claims 1-16.
27. A bispecific antibody comprising:
- (i) a CD3 δ ϵ -binding heavy chain variable domain comprising CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 18 in a human VH framework;
 - (ii) a light chain variable domain comprising CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 69 in a human VL framework; and
 - (iii) a single chain variable domain that specifically binds to a pathogen antigen in single or in tandem configuration.
28. The bispecific antibody of claim 27, further comprising an Fc region.
29. The bispecific antibody of claim 28, wherein the CD3 δ ϵ -binding heavy chain variable domain comprises the sequence of SEQ ID NO: 18, the light chain variable domain comprises the sequence of SEQ ID NO: 69.